瑞思邁 RMD 深 滬
已收盤 09-19 16:00:00 美东时间
242.98
+4.950
+2.08%
華盛通- 最 高243.48
- 今 開240.82
- 成交量 112.80万股
- 最 低 236.97
- 昨 收 238.03
- 總市值 357.18亿
- 52周最高 255.1794
- 市盈率 靜 35.12
- 換手率 0.77%
- 52周最低 130.27
- 委 比 -86.49%
- 總股本 1.47亿
- 歷史最高 295.87
- 量 比 0.92
- 振 幅 2.73%
- 歷史最低 7.09
- 每 手 1
- 風險率 29.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ResMed slips as Wolfe downgrades on GLP-1 threat from Lilly
ResMed (NYSE:RMD) shares fell Wednesday after Wolfe Research downgraded the MedTech, citing risks to the company’s CPAP (continuous positive airway pressure) device business from a potential label exp...
09-19 02:05
These are the mid-caps that could perform best during ‘downturn’ regimes – BofA
BofA Securities analysts listed 29 Russell MidCap (NYSEARCA:IWR) stocks that rank the highest among factors that have historically performed the best during “downturn regimes.” As BofA’s US Regime Ind...
09-19 02:00
Vivos surges on FDA nod for pediatric sleep apnea device
Shares of Vivos Therapeutics (NASDAQ:VVOS) climbed on Wednesday after MedTech announced the FDA's 510(k) clearance for its DNA appliance as a treatment for children with obstructive sleep apnea (OSA) ...
09-19 01:25
盘前：道指期货涨0.1% 美联储即将开启降息周期
美股股指期货周三盘前小幅攀升，全球市场在美联储的利率决议前保持观望态势，股票走势方向不明，美元下滑，而国债收益率小幅上升，投资者在权衡当天可能的大幅降息。...
09-18 20:30
Needham Reiterates Hold on ResMed
Needham analyst Mike Matson reiterates ResMed (NYSE:RMD) with a Hold.
09-18 18:06
美股异动丨瑞思迈盘前跌3.4% 机构下调其评级至“卖出”
瑞思迈(RMD.US)盘前跌3.43%报242.27美元。Wolfe Research将瑞思迈从同业表现下调至卖出评级，目标价格为180美元。另外，Farre...
09-18 17:25
Inspire Medical gains on GLP-1 prospects
Inspire Medical Systems (NYSE:INSP) traded higher on Wednesday after MedTech's CEO argued that the GLP-1 class of weight loss drugs could benefit its sleep apnea therapy business. "We are excited abou...
09-05 02:36
A Glimpse Into The Expert Outlook On ResMed Through 6 Analysts
Across the recent three months, 6 analysts have shared their insights on ResMed...
09-04 22:01
Needham Downgrades ResMed to Hold, Maintains $236 Price Target
Needham analyst Mike Matson downgrades ResMed (NYSE:RMD) from Buy to Hold and maintains $236 price target.
09-04 17:58
